[go: up one dir, main page]

WO1996040170A3 - Composes contenant des metaux et leur utilisation pour inhiber la reponse immunitaire - Google Patents

Composes contenant des metaux et leur utilisation pour inhiber la reponse immunitaire Download PDF

Info

Publication number
WO1996040170A3
WO1996040170A3 PCT/US1996/005942 US9605942W WO9640170A3 WO 1996040170 A3 WO1996040170 A3 WO 1996040170A3 US 9605942 W US9605942 W US 9605942W WO 9640170 A3 WO9640170 A3 WO 9640170A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
immune response
inhibiting
metal
containing compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/005942
Other languages
English (en)
Other versions
WO1996040170A2 (fr
Inventor
Cecilia M Bastos
Timothy D Ocain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procept Inc
Original Assignee
Procept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procept Inc filed Critical Procept Inc
Publication of WO1996040170A2 publication Critical patent/WO1996040170A2/fr
Publication of WO1996040170A3 publication Critical patent/WO1996040170A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur l'utilisation de composés en tant qu'immunodépresseurs servant à empêcher ou à diminuer de manière significative le rejet des greffons dans les greffes d'organe ou de moelle osseuse. Les composés de l'invention peuvent également s'utiliser comme immunodépresseurs dans les maladies auto-immunes à médiation thymodépendante, telles que le diabète, et peuvent être aussi bénéfiques pour soulager le psoriasis et l'eczéma de contact. Les composés peuvent également servir à des fins thérapeutiques dans le traitement des maladies vasculaires à évolution hyperchronique et pour réduire/supprimer la réponse immunitaire chez un patient subissant une thérapie génique.
PCT/US1996/005942 1995-06-07 1996-04-29 Composes contenant des metaux et leur utilisation pour inhiber la reponse immunitaire Ceased WO1996040170A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47934195A 1995-06-07 1995-06-07
US47295295A 1995-06-07 1995-06-07
US08/472,952 1995-06-07
US08/479,341 1995-06-07

Publications (2)

Publication Number Publication Date
WO1996040170A2 WO1996040170A2 (fr) 1996-12-19
WO1996040170A3 true WO1996040170A3 (fr) 1997-02-13

Family

ID=27043972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/005942 Ceased WO1996040170A2 (fr) 1995-06-07 1996-04-29 Composes contenant des metaux et leur utilisation pour inhiber la reponse immunitaire

Country Status (1)

Country Link
WO (1) WO1996040170A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19711800A1 (de) * 1997-03-21 1998-09-24 Hoechst Ag Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung
EP1391221A1 (fr) * 2002-08-23 2004-02-25 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Préparation pharmaceutique contenant des complexes de palladium pour le traitement du cancer et de maladies auto-immunes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0438756A1 (fr) * 1990-01-04 1991-07-31 SYMBIOTEC Gesellschaft zur Forschung und Entwicklung auf dem Gebiet der Biotechnologie GmbH Combinaisons d'agents actifs cytostatiques et cytotoxiques pour applications dans des méthodes thérapeutiques
US5512687A (en) * 1994-10-28 1996-04-30 Procept, Inc. Compounds for inhibiting immune response

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0438756A1 (fr) * 1990-01-04 1991-07-31 SYMBIOTEC Gesellschaft zur Forschung und Entwicklung auf dem Gebiet der Biotechnologie GmbH Combinaisons d'agents actifs cytostatiques et cytotoxiques pour applications dans des méthodes thérapeutiques
US5512687A (en) * 1994-10-28 1996-04-30 Procept, Inc. Compounds for inhibiting immune response

Also Published As

Publication number Publication date
WO1996040170A2 (fr) 1996-12-19

Similar Documents

Publication Publication Date Title
Mochizuki et al. A clinical trial of FK506 in refractory uveitis
Washton et al. Clonidine for opiate detoxification: outpatient clinical trials.
CA2229282A1 (fr) Utilisation d'acide hyaluronique en qualite d'agent immunosuppresseur
WO1992021313A3 (fr) Nouveaux composes immunosuppresseurs
CA2238098A1 (fr) Utilisation d'inhibiteurs de la nadph-oxydase pour la preparation d'un medicament destine a la prevention de l'atherosclerose
AU1032888A (en) Thermophilic microbial treatment of precious metal ores
EP1438966A3 (fr) Utilisation de depsipeptides et ses congénères dans le traitement d'une maladie infectieuse, d'une maladie autoimmune, d'allergies et d'une maladie hyperproliférative de lla peau.
CA2276606A1 (fr) Procede de traitement de maladies prostatiques au moyen d'analogues actifs de la vitamine d
HUT68332A (en) Novel immunsupressive compds. and pharmaceutical compns. contg. them
Duner et al. Histamine and leukocytes in blood during muscular work in man
KR910700055A (ko) 췌장염 및 췌장 이식시 면역 거부 반응 치료용 s-아데노실-메티오닌
MY105942A (en) Cyclosporin derivatives.
CA2006658A1 (fr) Une substance anticoagulante tiree de l'urine
WO2002026245A3 (fr) Methodes de traitement de reactions inflammatoires et immunitaires et compositions associees
AU6314296A (en) Therapeutic agents and autoimmune diseases
WO1996040170A3 (fr) Composes contenant des metaux et leur utilisation pour inhiber la reponse immunitaire
WO1996030042A3 (fr) Procedes pour le traitement des inflammations et compositions prevues a cet effet
HUP9802834A3 (en) Preparations for the treatment of t cell mediated autoimmune diseases
CA2385312A1 (fr) Compositions visant a prevenir et a traiter un rejet de greffon et techniques afferentes
WO2001035995A3 (fr) Agents de liaison specifiques a tr3 et procedes d'utilisation
WO1999056666A8 (fr) Traitement des troubles de la sexualite chez certains groupes de patients
Thrower et al. Thymopoietin in rheumatoid arthritis
AU6062294A (en) Treatment of gold bearing ore
IL108926A0 (en) Human t cell monoclone, process for its production and its use for the treatment and diagnosis of infectious diseases, autoimmune diseases, t-cell mediated allergies and cancer
AU6366994A (en) Methods for diagnosis and treatment of xscid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA